Medpace says second-quarter earnings and revenue beat estimates, backed by stronger bookings, backlog growth and higher 2026 guidance.
Medpace beat Q2 estimates with 17.2% revenue growth and raised FY2026 guidance; backlog at $3.01B with 1.13x book-to-bill. Strong CRO performance signals robust biotech R&D investment, key indicator for tech stack spending in drug discovery.
Medpace Holdings Inc.
(NASDAQ:MEDP) stock is trading higher on Thursday on better-than-expected second-quarter financial results and raised its fiscal 2026 guidance.
The clinical contract research organization reported earnings of $4.25, beating the consensus of $3.97.
The company reported sales of $707.33 million, surpassing the consensus of $687.65 million.
Revenues increased 17.2% year over year, representing a backlog conversion rate of 24.1%.
Medpace Notches A Surprise Beat, Sending Shares Skyward
Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026
P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Medpace stock surged by double digits Thursday, helped by a bookings beat.
Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud…
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action…
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit
MEDP Deadline: Rosen Law Firm Urges Medpace Holdings, Inc. (NASDAQ: MEDP) Stockholders to Contact the Firm for Information About…
